

Decision Biomarkers Inc Announces Formation of Scientific Advisory Board

WALTHAM, MA – November 20, 2008 – Decision Biomarkers Inc, a leading developer of protein biomarker analysis systems for pharmaceutical research and development, today announced the formation of a Scientific Advisory Board consisting of internationally renowned scientists and physicians at the forefront of biomarker and clinical research. The Scientific Advisory Board includes:

- **Daniel W. Chan**, Ph.D., Director of the Center for Biomarker Discovery and Director, Clinical Chemistry Division, at Johns Hopkins Medical Institution. In addition to his responsibilities of heading the hospital clinical chemistry laboratory, Dr. Chan conducts cutting edge research using state of the art proteomic techniques for biomarker discovery. His overall goals are the identification and characterization of novel biomarkers for the diagnosis and treatment of cancer.
- **Johann de Bono**, M.D., Ph.D., Senior Lecturer at The Institute for Cancer Research, Royal Marsden Hospital. Dr. de Bono is leader of the Prostate Cancer Team and directs the clinical drug development Phase I trials program at Royal Marsden Hospital, with a particular interest in pharmacokinetic – pharmacodynamic evaluation of targeted therapeutics.
- **John Heymach**, M.D., Ph.D., Assistant Professor of Thoracic Head/Neck Medical Oncology at the University of Texas MD Anderson Cancer Center. The goal of Dr. Heymach's clinical, translational and laboratory research is to advance the development of targeted agents, particularly angiogenesis inhibitors for non-small lung cancer, by incorporating biomarkers into clinical trials to improve patient outcomes.
- **Peter Maimonis**, Ph.D. Vice President of Biological Research, Decision Biomarkers, Waltham, MA. Dr. Maimonis has been involved in the discovery and validation of tumor biomarkers for over 20 years. His research has focused on diagnostic markers for breast and colorectal cancer. He has also developed assays for many of these biomarkers, taking a number of them through FDA approval.
- **Larry Oliver**, Ph.D., Scientific Director of Mayo Clinical Trial Services and Director of the Metals Laboratory in the Department of Laboratory Medicine and Pathology at Mayo Clinic, Rochester, MN. Dr. Oliver's research includes performance definitions of surrogate biomarkers of efficacy, antibody-antigen binding characterization, and clinical and analytical validation of biomarkers of safety.

“We are extremely pleased to have recruited such an outstanding group of visionary thought leaders to our SAB”, said Roger Dowd, President and CEO of DBI. “We look forward to their expert guidance to enable us to realize the full potential of our multiplex immunoassay technology for drug development”.

About Decision Biomarkers Inc

Decision Biomarkers is a privately-held life science tools company that has developed the next-generation technology for protein biomarker analysis. DBI is driving productivity improvement in the pharmaceutical and diagnostic industries by supplying automated, multiplex protein biomarker systems that can be used by virtually anyone, anywhere and in real time.

www.decisionbiomarkers.com

Copyright © 2008 Decision Biomarkers, Inc. All rights reserved.

For More Information:

Glenn Barney
Vice President
+17818902006